Abstract
The chimeric antigen receptor (CAR) technology started out as a tool to understand lymphocyte biology but rapidly developed into a T cell therapeutic agent for the treatment of cancers. Here, we describe the technological advances in the field of CARs and highlight critical components of its success. Additionally, we describe how various laboratories have worked toward developing new, safer, and more potent CARs for cancer.
Keywords: Cell therapy, chimeric antigen receptor (CAR), gene therapy, synthetic biology.
Current Drug Targets
Title:Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Volume: 18 Issue: 3
Author(s): Jan J. Melenhorst, Simon F. Lacey and Felipe Bedoya
Affiliation:
Keywords: Cell therapy, chimeric antigen receptor (CAR), gene therapy, synthetic biology.
Abstract: The chimeric antigen receptor (CAR) technology started out as a tool to understand lymphocyte biology but rapidly developed into a T cell therapeutic agent for the treatment of cancers. Here, we describe the technological advances in the field of CARs and highlight critical components of its success. Additionally, we describe how various laboratories have worked toward developing new, safer, and more potent CARs for cancer.
Export Options
About this article
Cite this article as:
Melenhorst J. Jan, Lacey F. Simon and Bedoya Felipe, Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer, Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450116666150825120427
DOI https://dx.doi.org/10.2174/1389450116666150825120427 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry PPARγ Agonists in Combination Cancer Therapies
Current Cancer Drug Targets Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part I
Anti-Cancer Agents in Medicinal Chemistry Apoptosis and Anti-cancer Drug Discovery: The Power of Medicinal Fungi and Plants
Current Medicinal Chemistry Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Epigenetics of Virus-Induced Tumors: Perspectives for Therapeutic Targeting
Current Pharmaceutical Design Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Protectors of the Mitochondrial Permeability Transition Pore Activated by Iron and Doxorubicin
Current Cancer Drug Targets